Orthofix International N.V. (OFIX) Given Average Recommendation of “Buy” by Brokerages

Orthofix International N.V. (NASDAQ:OFIX) has been given an average rating of “Buy” by the eight research firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $53.30.

A number of research firms recently commented on OFIX. BidaskClub upgraded Orthofix International from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Zacks Investment Research upgraded Orthofix International from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a report on Thursday, November 2nd. TheStreet downgraded Orthofix International from a “b” rating to a “c+” rating in a report on Tuesday, October 31st. Finally, BTIG Research set a $56.00 price target on Orthofix International and gave the stock a “buy” rating in a report on Monday, October 30th.

Shares of Orthofix International (NASDAQ OFIX) opened at $54.70 on Tuesday. The company has a market capitalization of $997.24, a PE ratio of 781.54, a P/E/G ratio of 2.71 and a beta of 0.14. Orthofix International has a fifty-two week low of $33.51 and a fifty-two week high of $56.53.

Orthofix International (NASDAQ:OFIX) last released its quarterly earnings data on Monday, October 30th. The medical device company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. The business had revenue of $105.30 million during the quarter, compared to the consensus estimate of $100.67 million. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.36 earnings per share. equities analysts expect that Orthofix International will post 1.61 earnings per share for the current fiscal year.

In other Orthofix International news, CEO Brad Mason sold 5,000 shares of the stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $53.48, for a total value of $267,400.00. Following the completion of the sale, the chief executive officer now directly owns 183,053 shares in the company, valued at $9,789,674.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Bradley V. Niemann sold 5,547 shares of the stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $52.08, for a total value of $288,887.76. Following the transaction, the insider now owns 34,631 shares of the company’s stock, valued at $1,803,582.48. The disclosure for this sale can be found here. Insiders sold 15,347 shares of company stock valued at $802,144 over the last 90 days. Corporate insiders own 5.60% of the company’s stock.

Several large investors have recently bought and sold shares of OFIX. Municipal Employees Retirement System of Michigan bought a new position in shares of Orthofix International during the second quarter worth about $196,000. Arizona State Retirement System grew its holdings in shares of Orthofix International by 1.1% during the second quarter. Arizona State Retirement System now owns 9,400 shares of the medical device company’s stock worth $437,000 after buying an additional 100 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Orthofix International by 2.9% during the second quarter. Rhumbline Advisers now owns 38,713 shares of the medical device company’s stock worth $1,799,000 after buying an additional 1,103 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Orthofix International by 11.2% during the second quarter. Legal & General Group Plc now owns 34,414 shares of the medical device company’s stock worth $1,599,000 after buying an additional 3,454 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Orthofix International by 64.3% during the second quarter. BNP Paribas Arbitrage SA now owns 7,651 shares of the medical device company’s stock worth $356,000 after buying an additional 2,995 shares in the last quarter. Institutional investors and hedge funds own 94.61% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Orthofix International N.V. (OFIX) Given Average Recommendation of “Buy” by Brokerages” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.chaffeybreeze.com/2018/01/02/orthofix-international-n-v-ofix-given-average-recommendation-of-buy-by-brokerages.html.

About Orthofix International

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Analyst Recommendations for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply